This article was originally published in Start Up
Amplistar is pursuing an entirely new approach to cancer diagnostics, one it hopes will allow both earlier and more effective detection of the diseases. Rather than measuring tumor marker proteins (like PSA for prostate cancer, or CA-125 for ovarian cancer), Amplistar aims to identify those tumor targets that produce an immune response in the body. The company believes that antibodies generated in response to tumor antigens may be detectable in the blood earlier than tumor marker proteins.
You may also be interested in...
New hunters of diagnostic biomarkers hope to improve cancer diagnosis. They envision biomarkers that will allow more accurate disease-stage monitoring, more effective choice of therapy and, ultimately, the development of therapies themselves. Despite the plethora of new technologies, tools, and genomic data, however, cancer-specific markers have provent obe difficult beasts to catch.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker